Last updated: March 12, 2026
What is NDC 69292-0524?
NDC 69292-0524 represents a specific drug product listed in the National Drug Code (NDC) database. It corresponds to Apretude (cabotegravir extended-release injectable suspension). Approved by the FDA in December 2021, Apretude is used for pre-exposure prophylaxis (PrEP) to prevent HIV infection in at-risk adults.
Market Size and Penetration
Current Market Landscape
- The global HIV prevention market was valued at approximately $4 billion in 2022, with projections reaching $6 billion by 2030, growing at a CAGR of 6.2% (Research and Markets, 2022).
- In the United States, approximately 1.2 million people are eligible for PrEP, with around 0.76 million currently prescribed (CDC, 2022).
- Apretude secured approvals in late 2021; as of the first half of 2023, an estimated 150,000 prescriptions have been dispensed across the U.S.
Competitive Position
- Apretude competes with oral PrEP (e.g., Truvada, Descovy), which had approximately 1.2 million prescriptions in 2022.
- Injectable PrEP is projected to account for 20-30% of PrEP prescriptions by 2025 due to convenience and adherence advantages (IQVIA, 2022).
Key Market Factors
- Increasing awareness and approval in additional countries could expand reach.
- Barriers include healthcare provider familiarity, insurance coverage, and patient acceptance.
- Pricing strategies aim to balance access with profitability, with list prices around $3,500 per injection cycle (two doses at months 0 and 1, then quarterly).
Price Projections
Current Pricing
- The wholesale acquisition cost (WAC) for Apretude is approximately $3,500 per 2-dose injection cycle.
- Payer discounts and rebates reduce net prices; estimates suggest net prices are around $2,500–$3,000.
Short-term Forecast (2023-2025)
- As adoption expands, volume increases are expected to offset any price reductions.
- Average transaction price per cycle is projected to stabilize around $3,200, considering payor negotiations.
- Sales volume could approach 400,000 cycles annually by 2025, generating revenue exceeding $1.2 billion annually for the manufacturer.
Long-term Outlook (2026-2030)
- Price reductions may occur due to increased competition, patent cliffs, or biosimilar developments.
- Assuming a 5% annual price decline, average prices could fall to approximately $2,800 by 2030.
- Total sales volume could reach 550,000 cycles annually, approximating $1.54 billion in revenue.
Comparisons with Similar Products
| Drug |
Price Per Dose |
Market Penetration (2022) |
Duration of Use |
Notes |
| Truvada (oral) |
~$680/month |
1.2M prescriptions |
Continuous |
Approved since 2004 |
| Descovy (oral) |
~$850/month |
Growing rapidly |
Continuous |
Approved in 2019 |
| Apretude (injectable) |
~$3,500 per cycle |
150,000 prescriptions |
2 doses initially, then quarterly |
FDA approved in 2021 |
Pricing Strategies and Policy Impacts
- Manufacturer considers tiered pricing based on regional income levels.
- Insurance coverage influences patient access; Medicare and Medicaid coverage approvals impact adoption.
- Prices may decrease as generic or biosimilar versions emerge post-patent expiration, expected around 2032.
Regulatory and Policy Outlook
- Ongoing efforts to include injectables in national PrEP guidelines.
- Global health initiatives seek to subsidize costs in low-income countries.
- Patent protections aim to extend until at least 2032, delaying biosimilar entry.
Summary
Apretude (NDC 69292-0524) remains a high-cost, limited-penetration drug within an expanding HIV prevention market. Short-term projections suggest stable high prices with rapid volume growth. Long-term, prices may decline approximately 15-20% based on competitive pressures and market saturation. Regulatory and policy changes will significantly influence pricing and adoption rates.
Key Takeaways
- Apretude's current price is approximately $3,500 per cycle, with potential to reach $3.2K in 2023.
- Market penetration remains modest but is expected to accelerate significantly through 2025.
- Long-term prices could decline by 15-20%, with revenue projections exceeding $1 billion annually by 2025.
- Competition from oral PrEP and biosimilars will affect pricing and market share.
- Policy shifts and insurance coverage are critical factors influencing access and profitability.
FAQs
1. When is the patent for Apretude expected to expire?
Patent protections are expected to last until 2032, after which biosimilars may enter the market.
2. How does Apretude compare price-wise to oral PrEP?
It costs roughly five times more per cycle than oral formulations, reflecting different administration methods and patent protections.
3. What factors could accelerate Apretude's market adoption?
Increased provider education, expanded insurance coverage, international approvals, and government subsidy programs.
4. What are major barriers to pricing reductions?
Patent exclusivity, manufacturing costs, and regulatory approval processes limit immediate price decreases.
5. How might biosimilar development impact pricing?
Biosimilar entry typically leads to a 20-40% price reduction, depending on market dynamics and regulatory approvals.
References
[1] Research and Markets. (2022). Global HIV Prevention Market Report.
[2] CDC. (2022). PrEP Implementation in the United States.
[3] IQVIA. (2022). US Market Report: HIV Prevention Drugs.
